Method for diagnosing and prognosing Inflammatory Bowel Disease and Crohn's disease
AssigneeGlycominds Ltd.
InventorsNir Dotan, Avinoam Dukler, Rom Altstock
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.
Claims54
A method for diagnosing severe Crohn's disease in a subject, the method comprising,
- providing a test sample from a subject with symptoms of Crohn's disease;
- and
- determining whether said sample includes an antibody selected from an antibody selected from the group consisting of an anti-Glc(β1,3)Glc(β) antibody (ALCA), anti-Glc(β1,6)Glc(β) antibody, an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA), an anti-α-GalNAc antibody (AGCA), an anti-β-GalNAc antibody, and an anti-laminarin antibody,
- wherein the presence of said antibodies in said test sample indicates the subject has severe Crohn's disease.
The method of claim 2, wherein said method includes determining whether said sample includes two antibodies selected from the group consisting of an anti-Glc(β1,3)Glc(β) antibody (ALCA), anti-Glc(β1,6)Glc(β) antibody, an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA), an anti-α-GalNAc antibody (AGCA), an anti-β-GalNAc antibody, and an anti-laminarin antibody.
The method of 19, the anti-Glc(β1,3)Glc(β) antibody (ALCA), anti-Glc(β1,6)Glc(β) antibody, the anti-α-GalNAc antibody (AGCA), the anti-β-GalNAc, and the anti-laminarin antibody are IgG antibodies and the anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA) and the anti-β-GalNAc antibody are IgA antibodies
A method for assessing the prognosis of Crohn's disease complications in a subject, the method comprising
- providing a test sample from a subject with symptoms of Crohn's disease;
- and
- determining whether said sample includes an antibody selected from an antibody selected from the group consisting of an anti-Glc(β1,3)Glc(β) antibody (ALCA), anti-Glc(β1,6)Glc(β) antibody an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA), an anti-α-GalNAc antibody (AGCA), an anti-β-GalNAc antibody, an anti-Glc(α1,6) Glc(α) antibody, and an anti-laminarin antibody,
- wherein the presence of said antibodies in said test sample indicates a severe Crohn's disease prognosis for said subject.
A method for assessing the prognosis of Crohn's disease complications in a subject, the method comprising
- providing a test sample from a subject with symptoms of Crohn's disease;
- and
- determining whether said sample includes an anti-Glc(β1,3)Glc(β) antibody (ALCA), an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA), an anti-Man(α1,3)Man(α) antibody (AMBA), and an anti-Mannan antibody,
- wherein the presence of said antibodies in said test sample indicates a severe Crohn's disease prognosis for said subject.
A method for differentiating inflammatory bowel disease (IBD) from a disease other than IBD in subject, the method comprising
- providing a test sample from a subject with symptoms of IBD;
- and
- determining whether said sample includes determining whether said sample includes an antibody selected from an antibody selected from the group consisting of an anti-Glc(β1,3)Glc(β) antibody (ALCA), an anti-Glc(β1,6)Glc(β) antibody, an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA), an anti-α-GalNAc antibody (AGCA), an anti-β-GalNAc antibody, and an anti-laminarin antibody,
- wherein the presence of said antibodies in said test sample indicates the subject has inflammatory bowel disease.
Dependencies are inferred from the claim text.